MA54856A - Monohydrate de chlorhydrate de rogaratinib et états solides associés - Google Patents

Monohydrate de chlorhydrate de rogaratinib et états solides associés

Info

Publication number
MA54856A
MA54856A MA054856A MA54856A MA54856A MA 54856 A MA54856 A MA 54856A MA 054856 A MA054856 A MA 054856A MA 54856 A MA54856 A MA 54856A MA 54856 A MA54856 A MA 54856A
Authority
MA
Morocco
Prior art keywords
rogaratinib
hydrochloride monohydrate
solid states
associated solid
states
Prior art date
Application number
MA054856A
Other languages
English (en)
Inventor
Jörg Gries
Claus-Christian Häselhoff
Kai Lovis
Johannes Platzek
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of MA54856A publication Critical patent/MA54856A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA054856A 2019-01-31 2020-01-27 Monohydrate de chlorhydrate de rogaratinib et états solides associés MA54856A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19154781 2019-01-31

Publications (1)

Publication Number Publication Date
MA54856A true MA54856A (fr) 2022-05-04

Family

ID=65276007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054856A MA54856A (fr) 2019-01-31 2020-01-27 Monohydrate de chlorhydrate de rogaratinib et états solides associés

Country Status (22)

Country Link
US (1) US20220098201A1 (fr)
EP (1) EP3917929A1 (fr)
JP (1) JP2022519081A (fr)
KR (1) KR20210119994A (fr)
CN (1) CN113382997A (fr)
AU (1) AU2020214188A1 (fr)
BR (1) BR112021012876A2 (fr)
CA (1) CA3128073A1 (fr)
CL (1) CL2021001977A1 (fr)
CO (1) CO2021009660A2 (fr)
DO (1) DOP2021000162A (fr)
EA (1) EA202192133A1 (fr)
EC (1) ECSP21056314A (fr)
GE (2) GEP20237531B (fr)
IL (1) IL284927A (fr)
JO (1) JOP20210204A1 (fr)
MA (1) MA54856A (fr)
MX (1) MX2021009173A (fr)
PH (1) PH12021551812A1 (fr)
SG (1) SG11202107919YA (fr)
TW (1) TW202035413A (fr)
WO (1) WO2020156982A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978830A1 (fr) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Combinaisons contenant des 2,3-dihydroimidazo[1,2-c]quinazoline substituees
CN113720956B (zh) * 2021-09-08 2022-03-29 广州国标检验检测有限公司 一种气质联用检测药物中硫酸酯的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
TW200801008A (en) * 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos

Also Published As

Publication number Publication date
US20220098201A1 (en) 2022-03-31
JP2022519081A (ja) 2022-03-18
EA202192133A1 (ru) 2022-02-09
CN113382997A (zh) 2021-09-10
EP3917929A1 (fr) 2021-12-08
WO2020156982A1 (fr) 2020-08-06
DOP2021000162A (es) 2021-09-15
ECSP21056314A (es) 2021-08-31
TW202035413A (zh) 2020-10-01
PH12021551812A1 (en) 2022-03-21
CA3128073A1 (fr) 2020-08-06
CL2021001977A1 (es) 2022-02-25
CO2021009660A2 (es) 2021-08-09
AU2020214188A1 (en) 2021-07-15
MX2021009173A (es) 2021-09-10
IL284927A (en) 2021-09-30
GEAP202315724A (en) 2023-05-10
GEP20237531B (en) 2023-08-25
JOP20210204A1 (ar) 2023-01-30
KR20210119994A (ko) 2021-10-06
BR112021012876A2 (pt) 2021-09-08
SG11202107919YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3904351A4 (fr) Inhibiteur de fak et combinaison de médicaments associée
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
EP3845532A4 (fr) Dérivé de quinolino-pyrrolidin-2-one et application associée
EP3749311A4 (fr) Compositions de pémétrexed polyglutamaté gamma et leurs utilisations
DK3737765T4 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
IL284799A (en) Tyk2 inhibitors and uses thereof
LT3452485T (lt) Arginazės inhibitoriai ir jų terapinis taikymas
EP3353175A4 (fr) Sels et formes solides d'antibiotique monobactame
EP3609864C0 (fr) Inhibiteurs de hdac6 et agents d'imagerie
IL291217A (en) Usp30 inhibitors and uses thereof
IL283938B2 (en) History of oxypyrimidinyl-methyl-benzamide and their deuterated forms and pharmaceutical preparations containing them
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
IL285118A (en) Compounds and uses thereof
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
PT4011898T (pt) Derivado de 3-hidroxi-5-pregnano-20-ona e sua utilização
EP3773654C0 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
IL282157A (en) Compounds and therapeutic uses thereof
EP4017857A4 (fr) Inhibiteurs de mettl 16 et leurs utilisations
DK3908321T3 (da) Farmaceutisk sammensætning
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
IL284927A (en) The monohydrate of rogaratinib hydrochloride and solid states thereof